265 related articles for article (PubMed ID: 31217428)
1. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.
Minuesa G; Albanese SK; Xie W; Kazansky Y; Worroll D; Chow A; Schurer A; Park SM; Rotsides CZ; Taggart J; Rizzi A; Naden LN; Chou T; Gourkanti S; Cappel D; Passarelli MC; Fairchild L; Adura C; Glickman JF; Schulman J; Famulare C; Patel M; Eibl JK; Ross GM; Bhattacharya S; Tan DS; Leslie CS; Beuming T; Patel DJ; Goldgur Y; Chodera JD; Kharas MG
Nat Commun; 2019 Jun; 10(1):2691. PubMed ID: 31217428
[TBL] [Abstract][Full Text] [Related]
2. Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.
Han Y; Ye A; Zhang Y; Cai Z; Wang W; Sun L; Jiang S; Wu J; Yu K; Zhang S
PLoS One; 2015; 10(8):e0136484. PubMed ID: 26308531
[TBL] [Abstract][Full Text] [Related]
3. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
[TBL] [Abstract][Full Text] [Related]
4. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
Palacios F; Yan XJ; Ferrer G; Chen SS; Vergani S; Yang X; Gardner J; Barrientos JC; Rock P; Burack R; Kolitz JE; Allen SL; Kharas MG; Abdel-Wahab O; Rai KR; Chiorazzi N
Leukemia; 2021 Apr; 35(4):1037-1052. PubMed ID: 33504942
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
Duggimpudi S; Kloetgen A; Maney SK; Münch PC; Hezaveh K; Shaykhalishahi H; Hoyer W; McHardy AC; Lang PA; Borkhardt A; Hoell JI
J Biol Chem; 2018 Oct; 293(40):15359-15369. PubMed ID: 30126842
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-143 acts as a tumor suppressor through Musashi-2/DLL1/Notch1 and Musashi-2/Snail1/MMPs axes in acute myeloid leukemia.
Li F; Han Y; Chen R; Jiang Y; Chen C; Wang X; Zhou J; Xu Q; Jiang S; Zhang S; Yu K; Zhang S
J Transl Med; 2023 May; 21(1):309. PubMed ID: 37149661
[TBL] [Abstract][Full Text] [Related]
7. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia.
Ge Y; Schuster MB; Pundhir S; Rapin N; Bagger FO; Sidiropoulos N; Hashem N; Porse BT
Nat Commun; 2019 Jan; 10(1):172. PubMed ID: 30635567
[TBL] [Abstract][Full Text] [Related]
8. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.
Vu LP; Prieto C; Amin EM; Chhangawala S; Krivtsov A; Calvo-Vidal MN; Chou T; Chow A; Minuesa G; Park SM; Barlowe TS; Taggart J; Tivnan P; Deering RP; Chu LP; Kwon JA; Meydan C; Perales-Paton J; Arshi A; Gönen M; Famulare C; Patel M; Paietta E; Tallman MS; Lu Y; Glass J; Garret-Bakelman FE; Melnick A; Levine R; Al-Shahrour F; Järås M; Hacohen N; Hwang A; Garippa R; Lengner CJ; Armstrong SA; Cerchietti L; Cowley GS; Root D; Doench J; Leslie C; Ebert BL; Kharas MG
Nat Genet; 2017 Jun; 49(6):866-875. PubMed ID: 28436985
[TBL] [Abstract][Full Text] [Related]
9. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M; Gokhale PC; Barbie D; Mullally A; Stegmaier K; Frank DA
Blood Adv; 2018 Dec; 2(23):3428-3442. PubMed ID: 30504235
[TBL] [Abstract][Full Text] [Related]
10. [Expression of musashi-2 gene in leukemia stem cells from acute myeloid leukemia patients].
Ye AF; Han YX; Zhang SH; Li HY; Chen CQ; Wu JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1235-8. PubMed ID: 25338564
[TBL] [Abstract][Full Text] [Related]
11. Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1.
Lan L; Xing M; Kashipathy M; Douglas J; Gao P; Battaile K; Hanzlik R; Lovell S; Xu L
Proteins; 2020 Apr; 88(4):573-583. PubMed ID: 31603583
[TBL] [Abstract][Full Text] [Related]
12. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.
Park SM; Gönen M; Vu L; Minuesa G; Tivnan P; Barlowe TS; Taggart J; Lu Y; Deering RP; Hacohen N; Figueroa ME; Paietta E; Fernandez HF; Tallman MS; Melnick A; Levine R; Leslie C; Lengner CJ; Kharas MG
J Clin Invest; 2015 Mar; 125(3):1286-98. PubMed ID: 25664853
[TBL] [Abstract][Full Text] [Related]
13. l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)
Song JH; Park E; Kim MS; Cho KM; Park SH; Lee A; Song J; Kim HJ; Koh JT; Kim TS
Int J Cancer; 2017 May; 140(10):2364-2374. PubMed ID: 28224619
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the drugability of MSI2 RNA recognition motif (RRM) protein and the prediction of their effective antileukemia inhibitors from traditional herb concoctions.
Adeniyi JN; Adeniyi AA; Moodley R; Nlooto M; Ngcobo M; Gomo E; Conradie J
J Biomol Struct Dyn; 2022 Apr; 40(6):2516-2529. PubMed ID: 33131412
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
16. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
17. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
18. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated Stem Cell Markers Musashi-1 and Musashi-2 are Associated with Therapy Resistance in Inflammatory Breast Cancer.
Haiduk TS; Sicking M; Brücksken KA; Espinoza-Sánchez NA; Eder KM; Kemper B; Eich HT; Götte M; Greve B; Troschel FM
Arch Med Res; 2023 Sep; 54(6):102855. PubMed ID: 37481823
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule Ro-08-2750 interacts with many RNA-binding proteins and elicits MUSASHI2-independent phenotypes.
Walters K; Sajek MP; Murphy E; Issaian A; Baldwin A; Harrison E; Daniels M; Reisz JA; Hansen K; D'Alessandro A; Mukherjee N
RNA; 2023 Oct; 29(10):1458-1470. PubMed ID: 37369529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
